FDR analysis indicated that the combined HRs of the XRCC1 Gln and XPD Gln allelic variants in stage II/III colon cancer patients (HR  = 2.60; FDR  = 0.102) and the XRCC1 Arg/Arg and XPD Gln allelic variants in stage II/III rectal cancer patients (HR  = 2.77; FDR  = 0.102) were not significantly influenced by type I error because of multiple comparisons. This evidence concerns the gene ERCC2 and rectal cancer.